Institute of Cancer Research

Recent papers from Institute of Cancer Research

1. Rapid early degradation of Cyclin A is important to maintain genomic stability2026
2. Intravenous thrombolysis versus non-thrombolytic standard care for lacunar ischaemic stroke: a protocol for a systematic review and meta-analysisBMJ Open · 2026
3. Cerebrospinal fluid and plasma circulating tumor DNA dynamics as a biomarker of response during trastuzumab deruxtecan treatment in patients with breast cancer with leptomeningeal diseaseClinical Cancer Research · 2026
4. Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8⁺ T-cell clonal dominance in head and neck cancerCancer Immunology Research · 2026
5. Preliminary evaluation of ProSpare®, a rectal obturator for prostate bed radiotherapy within the randomised multicentre POPS trial (NCT02978014)Frontiers in Oncology · 2026
6. Longitudinal liquid biopsy and matched radiomic analysis indicated resistance mechanisms of patients with biliary tract cancer undergoing systemic treatment.Clinical Cancer Research · 2026
7. Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Randomized StudyCancer Research Communications · 2026
8. Clinical and Molecular Profiles of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancers in the Era of Intensified Systemic TherapiesCancer Research Communications · 2026
9. Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUSJournal of Clinical Oncology · 2026
10. COSMIC-005: Dark Energy Trend Persistence in the DESI Five-Year Dataset (Preregistration)2026
11. GPT-assisted radiomic modeling for predicting pathological complete response to neoadjuvant chemoimmunotherapy in head and neck squamous cell carcinomaPhysics in Medicine and Biology · 2026
12. Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 studyClinical Cancer Research · 2026
13. COSMIC-007: Large-Scale Structure Anisotropy in Rubin Observatory DR1 (Preregistration)2026
14. Closing the gap: the evolving landscape of integrative oncology education in the United StatesFrontiers in Oncology · 2026
15. Occupation and oncology: cancer care in PalestineFrontiers in Oncology · 2026
16. Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challengesFrontiers in Cell and Developmental Biology · 2026
17. Outbreaks of fluconazole-resistant Candida parapsilosis are driven by low-biofilm-producing isolates that emerge under host selectionPLoS Biology · 2026
18. 2 Relationships Between Plasma KIM-1 Levels, Peripheral Immune Profiles and Disease-Free Survival Outcomes in the TransRAMPART StudyThe Oncologist · 2026
19. 27 Development of Precision Virotherapies for Diffuse Midline GliomasNeuro-Oncology · 2026
20. 53 Analysis of translational challenges across 19 brain tumour therapeutic development programmes: Insights from the BTR-NTA acceleratorNeuro-Oncology · 2026